SOLAI Limited vs Smith & Nephew plc — how do they compare? SOLAI Limited trades at $3.72 (market cap $16.69M), while Smith & Nephew plc trades at $30.45 (market cap $12.64B). The key difference: Smith & Nephew plc is far larger — about 757.3× SOLAI Limited's market cap, and Smith & Nephew plc pays a 2.57% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| SLAI | SNN | |
|---|---|---|
Market Cap | $16.69M | $12.64B |
Sector | Technology | Health |
52-Week High | $26.74 | $38.70 |
52-Week Low | $2.74 | $28.73 |
Enterprise Value | $16.33M | $15.41B |
Dividend Yield | — | 2.57% |
Trailing returns across standard periods
Latest headlines on both assets
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →